OncoMatch/Clinical Trials/NCT06493370
Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer
Is NCT06493370 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Intravenous ascorbic acid/vitamin C for bladder cancer.
Treatment: Intravenous ascorbic acid/vitamin C — This is a phase II, single arm, Simon two-stage design, trial, enrolling patients with cisplatin ineligible MIBC and/or those patients who decline cisplatin based NAC. Assess rates of pathologic downstaging and quality of life in MIBC cisplatin-ineligible/declined patients when IVC is added to gemcitabine-carboplatin NAC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: G6PD normal (normal)
Normal Glucose-6-phosphate dehydrogenase (G6PD) status
Excluded: G6PD deficiency
History of G6PD deficiency
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute Neutrophil Count >1.5K/UL (patients with benign neutropenia eligible with ANC 1000-1500 at physician discretion); Platelets >100K/UL; Hemoglobin ≥ 9 g/dL
Kidney function
Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation
Liver function
Total bilirubin ≤ 2.0 x ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN
Adequate organ function, defined as follows: Absolute Neutrophil Count >1.5K/UL... Platelets >100K/UL; Hemoglobin ≥ 9 g/dL; Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 30 mL/min... Total bilirubin ≤ 2.0 x ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN; Normal Glucose-6-phosphate dehydrogenase (G6PD) status
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Holden Comprehensive Cancer Center - The University of Iowa · Iowa City, Iowa
- The University of Kansas Cancer Center · Kansas City, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06493370 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require G6PD?
Yes, G6PD normal is a required biomarker for enrollment.
Are patients with G6PD alterations eligible?
No. G6PD deficiency is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages